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Abstract
The inflammatory diseases of the nose, rhino-pharynx and paranasal sinuses (allergic and non allergic rhinitis,
NARES; rhinosinusitis with/without nasal polyposis, adenoidal hypertrophy with/without middle ear involvement)
clinically manifest themselves with symptoms and complications severely affecting quality of life and health care
expenditure.
Intranasal administration of corticosteroids, being fast, simple, and not requiring cooperation, is the preferred way
to treat the patients, to optimize their quality of life, at the same time minimizing the risk of exacerbations and
complications.
Among the different topical steroids available on the market, we performed a comparative analysis in terms of
effectiveness and safety between mometasone furoate (MF) and its main competitors.
Searching through Pub Med and Google Scholar and using as entries “mometasone furoate”, “rhinitis”, “sinusitis”,
“asthma”, “polyposis”, “otitis media with effusion”, and “adenoid hypertrophy” we found 344 articles, 300 of which
met the eligibility criteria.
Taking into account relevance and date of publication, a sample of 40 articles was considered for the review.
MF effectiveness for treatment and/or prophylaxis of nasal symptoms in seasonal and perennial allergic rhinitis has
been fully established with a level of evidence Ia.
Even though it has not been assessed for MF in particular, topical steroids are the most appropriate treatment in
mixed rhinitis and NARES.
In acute rhinosinusitis (ARS) evidences support their use as mono-therapy or as adjuvant to antibiotics for reducing
the recurrence rate, and decrease the usage of related prescriptions and medical consultations.
In chronic rhinosinusitis (CRS) with Nasal polyposis, MF reduces polyps size, nasal congestion, improves quality of
life and sense of smell and it is also effective in the treatment of daytime cough.
The topical use of MF has great efficacy in the management of adenoidal hypertrophy and otitis media of atopic
children.
As regards the safety, MF has demonstrated an excellent safety profile: pregnant women can safely use it; no
systemic effects on growth velocity and adrenal suppression have been shown; no changes in epithelial thickness
or atrophy have been observed after long term administration of the drug.
Conclusions: MF has been demonstrated to be effective in the treatment of the inflammatory diseases of the nose
and paranasal sinuses; when compared to its competitors it shows a greater symptom control; it is a reliable
treatment in the long term thanks not only to its proven efficacy, but also to its safety being on the market since
more than 17 years.
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Background
Rhinitis is a common inflammation of the nasal mem-
brane of the nose, caused by viruses, bacteria, and other
irritants as well as allergens. Even if it is usually associ-
ated with inflammation, some forms of rhinitis, such as
vasomotor or athrophic rhinitis, are not predominantly
inflammatory.
Chronic rhinosinusitis is an inflammatory condition of
the nose and paranasal sinuses defined by: presence of
two or more symptoms one of which should be either
nasal blockage/obstruction/congestion or nasal discharge
(anterior/posterior nasal drip) +/- facial pain/pressure; +/-
reduction or loss of smell in adults (+/- cough in children)
for ≥ 12 weeks (EPOS, 2012).
The persistent inflammatory condition of the nose and
paranasal sinuses clinically manifests itself with many
symptoms and complications, such as nasal congestion,
sneezing, coughing, headaches, rhinorrhea (anterior or
posterior), itching, malaise, pain, and fatigue. Those af-
flictions are frequently accompanied by symptoms in-
volving the eyes, ears and throat and combined together,
they all severely affect the quality of life.
Enlarged adenoids and infection of adenoid tissue may
lead to the obstruction of the breathing patterns in chil-
dren, causing apnea during sleep and contibuting to re-
curring sinusitis and persistent middle ear disease.
Rhinitis, as well as nasal congestion, may also lead to
airway obstruction and an increased number of sleep
microarousals, both in children and adults. Sleep distur-
bances can detrimentally affect daytime energy levels,
mood, and, consequently, determine daytime fatigue [1].
Combined together, these afflictions account for 1 to
2 % of total physician consultations and are associated
with large health care expenditure.
Main text
Appropriate use of medical therapies is necessary to
optimize patient quality of life and daily functioning and
minimize the risk of acute inflammatory exacerbations
and complications.
The most common therapies for the aforementioned dis-
eases are topical nasal sprays which could be natural or
pharmaceutical products. Intranasal route is generally pre-
ferred by both patients and doctors: it is fast, simple, does not
require cooperation, the drug assimilation is direct and quick
and compliance to therapy is high. Among these sprays, cor-
ticosteroid topical application is undoubtedly the most widely
used and most effective [2, 3] although minor side effects
could be reported (nose bleeding, dryness, crusting).
Glucocorticosteroids are used in upper airway diseases:
allergic and non allergic rhinitis, particularly non allergic
rhinitis with eosinophilia syndrome (NARES), acute and
chronic rhinosinusitis, with and without nasal polyps, ade-
noid hypertrophy with or without middle era disease.
There are many other possible therapies, either medical
or surgical, and especially for allergic rhinitis management
many different therapeutical strategies are available.
Effective measures include allergen avoidance (pollens,
fungi, dust), mite-proof covers, air filters and nasal irri-
gation, and the best results are obtained when combined
with intranasal steroids. Other pharmacological options
should be taken into account if those measures are not
effective, and they include antihistamine drugs, that
could be taken orally or nasally, pseudoephedrine, cro-
molyn, leukotriene receptor antagonists.
Thus far, evidence suggests that intranasal corticoste-
roids produce greater relief of nasal symptoms than top-
ical antihistamines (H1 receptor antagonists), even if no
difference in ocular symptoms has been reported [4].
Long-term tolerance to allergens can be induced by
immunotherapy, but the desensitiziation therapy is often
considered to be quite expensive [5]. Moreover, the cap-
acity of sublingual allergen immunotherapy (SLIT) to
provide effective symptom relief in seasonal allergic
rhinitis has also been questioned. It has been reported
that SLIT tablets had a greater clinical impact than
second-generation antihistamines and montelukast, but
when compared to nasal corticosteroids, the beneficial
effects were the same [6].
Alternative treatments such as acupuncture and hom-
eopathy, even if quite popular, are not supported by any
evidence.
Intranasal corticosteroids may be useful in the treat-
ment of some forms of non-allergic rhinitis and should
be an appropriate choice for mixed rhinitis. Evidence [7]
declares them to be useful for the treatment of non al-
lergic rhinitis with eosonophilia syndrome.
Also for chronic (CRS) and acute (ARS) rhinosinusitis
various topical therapies are available: saline solutions,
antibiotics, corticosteroids, and antifungals. Topical sa-
line and corticosteroids should be considered as the first
line of therapy for CRS [8] and evidence supports its use
as a monotherapy or as an adjuvant therapy to antibi-
otics in ARS [9].
Corticosteroid nasal sprays include: beclometasone
diproprionate, budesonide, ciclesonide, flunisolide, fluti-
casone furoate, fluticasone proprionate, triamcinolone
acetonide, and mometasone furoate.
With so many different sprays available in the market,
many authors decided to compare efficacy, side-effect
profile and relative cost of each product, to assess which
- and if - one is the best [2]. Results have too often been
controversial and there is no clear evidence in favour of
one or the other. Thus far it has been established that all
the sprays have a similar side-effect profile, and the most
significant differences might be related to patient's per-
sonal preference for each product sensory attributes
[10–12] and costs.
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Mometasone furoate (MF) is used in the treatment of
rhinitis and rhinosinusitis as well as asthma [13], inflam-
matory skin disorders and penile phimosis. Evidence
suggests that its usage improves symptoms related to ad-
enoid hypertrophy, too.
To assess MF nasal spray effectiveness and safety we
decided to analyze the scientific publications related to
this molecule and to perform a comparative analysis be-
tween MF and its main intranasal competitors.
Our work consisted in searching through Pub Med
and Google Scholar, using as entries: “mometasone
furoate”, “rhinitis”, “sinusitis”, “asthma”, “polyposis”,
“pediatric OSAS”, “otitis media with effusion” and “ade-
noid hypertrophy.”
The database search revealed 344 articles. Out of
these, 300 met eligibility criteria and were assessed inde-
pendently by two authors for further evaluation. A sam-
ple of 40 articles was considered for this review, taking
into account relevance and date of publication.
We then proceded to evaluate mometasone furoate
nasal spray efficacy, safety, and cost-effectivenes.
In 1998, mometasone furoate was introduced as a
nasal spray. MF has been largely successful since it was
first sold. Its dosage is 2 sprays/nostril once a day (50
mcg in each spray) and the dosage for children is halved
to 1 spray for each nostril daily. Evidence [14–16] shows
that - at least for asthma maintenance - 1spray daily should
be enough (thus diminishing both costs and side effects).
To obtain the best results, as most topical intranasal
corticosteroids, it is strongly suggested to blow the nose
to clear the passageway before the application or per-
form a nasal irrigation, and to avoid sneezing or blowing
the nose right after spraying.
MF usage for treatment and/or prophylaxis of the
nasal symptoms of seasonal allergic rhinitis and peren-
nial allergic rhinitis has been fully established and a level
of evidence Ia (Centre for Evidence Based Medicine,
Oxford 2009) has been provided [17, 18].
Intranasal corticosteroid therapy also has a beneficial
effect in relieving eye symptoms in allergic conjunctiv-
itis, similar to oral or intranasal antihistamines [19–21]
according to reviews.
Even though it has not been clearly assessed for MF in
particular, its usage should improve other forms of rhin-
itis, like mixed forms or NARES.
Compared with antibiotics monotherapy, using MF
nasal spray for initial ARS treatment, alone or combined
with an antibiotic, has been demonstrated to reduce the
recurrence rate and decrease the usage of related pre-
scriptions and medical consultations [22].
As regards the treatment of nasal polyposis, MF, if ad-
ministered daily, reduces polyp size and the nasal con-
gestion, improving quality of life and sense of smell,
with no unusual or unexpected adverse events [23–25].
Furthermore, regarding other minor complaints associ-
ated with rhinitis and rhinosinusitis, mometasone furoate
nasal spray has been shown to be safe, effective and well
tolerated in the treatment of daytime cough, too [26].
In 1998, Minshall et al. [27] evaluated patients before
and after treatment with MF nasal spray. Through nasal
biopsies, they assessed that long-term administration of
the drug attenuates the inflammatory process decreasing
the extent of inflammatory cell infiltration (especially eo-
sinophils) and did not determine changes in epithelial
thickness or atrophy.
It has also been well established that the topical use of
MF in the pediatric population shows great efficacy for
management of adenoidal hypertophy [28] and otitis
media with effusion [29], despite the concomitant pres-
ence of atopy [30]. Lastly, as reported in a recent cost-
effectiveness analysis [31] when compared to beclo-
methasone diproprionate, the therapy with mometasone
furoate for treating children suffering from allergic rhinitis
showed a greater improvement, better efficacy, safety, and
lower total treatment cost.
As regards the safety of the drug, the same results
were obtained when administered in children for nasal
polyps, even at double the recommended pediatric dos-
age for allergic rhinitis [32].
Pregnant women can safely use intranasal steroids.
The sprays work only in the nasal passageway and the
medicine does not affect other parts of the body unless
too much is used [3].
Until now, despite parents apprehension, topical appli-
cation of MF - respecting the recommended dosage -
has not shown systemic effects. Many studies have been
conducted to investigate its effects on growth velocity
and its potential to cause adrenal suppression [33, 34].
Thus far, no significant difference has been reported and
the current guidelines for asthma recommend inhaled
corticosteroids for the control of mild to severe persist-
ent asthma in adults as well as adolescents.
MF dry powder inhaler has been demonstrated to have
an excellent safety and efficacy profile, and during post-
marketing surveillance and in clinical trials no signifi-
cant adverse side effects have been reported. In addition,
its simple use seems to improve asthma management by
addressing issues that generally inhibit proper adherence
to therapy [35–38]. These considerations for the usage
of MF in asthma could be extended to MF administered
via the intranasal route.
Each steroid preparation comes with patient instruc-
tions for safe and effective use. For best results, the
medication should be used following this direction care-
fully and according to medical advice. Adherence to
long-term therapy is essential to have the desired results.
In fact, intermittent therapy may not guarantee the same
benefits.This is even more true in the case of a chronic
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disease. Moreover, non-adherence to treatment may also
require that, if an acute attack occurs, a higher dose of
medication would be required, and possibly even aster-
oid molecule orally or intramuscularly administered.
The large quantity of different preparations available
could also allow the doctor - in case of molecules with
the same efficacy, dosage and quality of the dispenser -
to choose the most convenient for the patient, taking
into account the expenses related with long term use.
Expenses are halved when analyzing children (up to
11 years of age), due to the fact that the recommmended
dosages are of one spray for each nostril once daily.
Many preference evaluation studies have been con-
ducted to assess MF sensory attributes and establish
patients’ preference. Patients’ choice/preference might
contribute to enhanced treatment outcomes, since it
could improve adherence to treatment [10–12]. Results
were not always in favour of MF, but Meltzer et al. [12]
reported it to be more agreeable according to users.
Last but not least, it is a fact that all steroids suppress
gene expression of factors responsible for generating and
supporting inflammatory processes but furoates earn
special attention as their lateral furoate ester chain
makes the molecules highly lipophilic. Thus, the mole-
culas are easily absorbed by mucous membranes, epithe-
lium and cell membrane phospholipids. This minimizes
their general action and maximizes local action [39].
Conclusions
MF has been demonstrated to be safe, effective and, if
compared to its competitors, it shows symptom control
greater than the other products in the market. Moreover,
even if its marketing might classify it as an “old” mol-
ecule, it is also true that over 17 years of proven efficacy
not only define it as reliable in the long term, but make
MF absolutely safe as well.
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